Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale patents


Recent patent applications related to Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale. Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale is listed as an Agent/Assignee. Note: Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale may have other listings under different names/spellings. We're not affiliated with Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale-related inventors


Pixel cell circuit and implant

A pixel cell circuit comprises an electrode, one or more main photosensitive elements electrically coupled to the electrode for outputting a stimulation signal to the electrode responsive to light illumination, and a shunt arrangement comprising a shunt switch electrically coupled in parallel across the one or more photosensitive elements, and... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia

The present invention relates to a vector which comprises a nucleic acid sequence encoding for the frataxin (FXN) gene for use in the prevention and treatment of neurological phenotype associated with Friedreich ataxia in a subject in need thereof.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods and pharmaceutical compositions for the treatment of filovirus infections

The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one oligonucleotide comprising the... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods for diagnosing hematological cancers

The present invention relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Orexin-b polypeptides and uses thereof

The present invention relates to Orexin-B polypeptides and uses thereof, in particular for the treatment of cancer. In particular, the polypeptide of the present invention comprises the amino acid sequence ranging from the amino acid residue at position 6 to the amino acid residue at position 28 in SEQ ID... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods for the prevention and the treatment of rapidly progressive glomerulonephritis

The present invention relates to the prevention and the treatment of rapidly progressive glomerulonephritis.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease

The present invention relates to antagonists of GDF11, for use in the treatment of malignant hematological disease, such as Acute Myeloid Leukemia (AML). The present invention also relates to a method for predicting the responsiveness of a patient affected with malignant haematological disease, such as Acute Myeloid Leukemia, to a... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods and pharmaceutical compositions for the treatment of ebola virus disease

The invention relates to methods and pharmaceutical compositions for the treatment of Ebola Virus Disease. In particular the present relates to a method of treating Ebola Virus Disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of Favipiravir.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Compositions and methods for antigen-specific tolerance

The invention is in the field of immunotherapy. More particularly, the invention provides a composition comprising a Heme Oxygenase-1 (HO-1) and antigens. Also provided herein are methods of administering the compositions of the invention by subcutaneous, intradermal or topical administration in a patient for inducing antigen-specific tolerance.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection

The present invention relates to antibodies or fragments thereof that specifically bind to glycoprotein (GP) of Ebola virus, and to their use for treating and diagnosing Ebola virus disease.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods and pharmaceutical compositions for the treatment of ischemic conditions

The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer

The invention relates to a proteasome inhibitor for use for treating and/or preventing a disorder related to an accumulation of a non-degraded abnormal protein, particularly a premature ageing disorder. The invention also relates to the use of proteasome inhibitors for attenuating physiological ageing. The invention also relates to the use... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Method and device for enhancing memory consolidation

The present invention relates to methods and devices to consolidate memory and/or cognitive functions by monitoring brain rhythms and delivering a stimulus at an appropriate stage of sleep cycle.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Mutated factor x polypeptides and uses thereof for the treatment of haemophilia

The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide wherein the heavy chain comprises at least one mutation selected from the group consisting of: —the mutation which consists of... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor

The invention is related to metabolically stable apelin analogs and their use for the prevention or the treatment of diseases mediated by the apelin receptor in particular of cardiovascular disease (heart failure, hypertension, pulmonary hypertension, kidney failure) and inappropriate vasopressin secretions (SIADH).... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Human monoclonal antibodies against axl

The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods of diagnosing cancer and of predicting response of cancer to dendrogenin a treatment

The present invention relates to methods for the diagnosis and the treatment of cancer, in particular breast cancer. In particular, the present invention relates to a method of diagnosing cancer in a subject comprising the steps of i) determining the expression level of hGSTA1 in a tumor sample obtained from... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Molecular targets for the treatment of wounds, in particular chronic wounds

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Acoustic imaging

According to the invention, n incident acoustic waves Ei(t), obtained by linearly combining n elemental incident waves E0i(t) with an encoding matrix Hc are consecutively transmitted in a medium to be imaged. n reverberated waves Ri(t) from the medium to be imaged are then consecutively detected, following the transmission of... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof

The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse

The present invention concerns a CDC25A phosphatase inhibitor for use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering or having suffered from cancer.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods for screening a subject for a cancer

The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor

The present invention relates to the use of MAP3K8 protein to predict clinical outcome of a patient affected with a cancer, in particular ovarian cancer, or to select a patient for a treatment comprising one MEK inhibitor. The invention further relates to a method for monitoring a patient affected with... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods and pharmaceutical compositions for the treatment of fibrosis

The present invention relates to methods and pharmaceutical compositions for the treatment of fibrosis. In particular, the present invention relates to a method of treating fibrosis in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one monoacylglycerol lipase (MGL) inhibitor.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Anti-neurotensin antibodies and uses thereof

The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

An anti-cd45rc antibody for use as drug

The invention relates to an isolated anti-CD45RC antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with CD45RC+ cells. The invention relates to... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Method for in vitro production of adipocyte progenitors and adipocytes

The present invention relates to a method for in vitro production of adipocyte progenitors and adipocytes from pluripotent stem cells, in particular from induced pluripotent stem cells, as well as to the use of the adipocyte progenitors and adipocytes thus obtained for therapeutic or screening purposes.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods for predicting response to dna repair pathway inhibitors in diffuse large b-cell lymphoma

)... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases

The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Methods for predicting the survival time of patients suffering from cancer

The present invention relates to methods for predicting the survival time of patients suffering from cancer. Said methods are based on the quantification and analysis of the cell free nucleic acids that are present in a sample from the patient and typically include the determination of the level of the... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

Isolated donor mhc-derived peptide and uses thereof

The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to isolated peptide of length ranging between 11 and 16 amino acids comprising the amino acid... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

New treating melanoma

The present invention relates to a TNFα blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

06/15/17 / #20170166625

Soluble monomeric anti-mullerian hormone receptor type ii fusion proteins and uses thereof

The present invention relates to soluble monomeric Anti-Mullerian Hormone Receptor type II (AMHRII) fusion proteins and uses thereof, in particular for detection or quantification of the bioactive cleaved form of Anti-Müillerian Hormone in a sample. In particular, the present invention relates to a soluble monomeric AMHRII fusion protein wherein one... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

06/08/17 / #20170160290

A new biomarker of chronic allograft nephropathy and of renal transplant rejection

The invention relates to a method for determining whether a renal transplanted patient is at risk of transplant rejection or CAN, comprising a step of determining the expression level of the periostin (POSTN) gene on a renal transplant biopsy obtained from said transplanted patient. The invention also relates to a... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

06/01/17 / #20170152557

Free nucleic acids and mirna as non-invasive determining embryo quality

The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non-invasive methods for determining the quality of an embryo by determining the level of the cell free nucleic acids or miR-29a or let7-b in the nucleic acid extract from a... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

06/01/17 / #20170152561

Methods employing circulating dna and mirna as biomarkers for female infertility

The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods for determining the ovarian reserve and ovarian function by determining the level of cell-free nucleic acids or the level of a miRNA species selected from miR_30_a or miR_140 or let_7_b or... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

05/11/17 / #20170128036

Method and device for functional imaging of the brain

Method for functional imaging of the brain, comprising the following steps: (a) a brain is imaged by ultrasound imaging in order to obtain a vascular image to be studied (IVO), (b) the vascular image to he studied (IVO) is compared automatically, by shape recognition, with a cerebral vascular atlas (AV),... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

05/11/17 / #20170130267

Methods for predicting acute rejection in heart recipients

The present invention relates to method for predicting acute rejection in heart recipients. In particular, the present invention relates to a method for predicting acute rejection in a heart recipient comprising the steps consisting of i) determining the expression level (ELi) of at least one miRNAi selected from the group... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

04/13/17 / #20170100378

Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes

The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

04/13/17 / #20170102389

New biomarker for outcome in aml patients

The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML) comprising i) determining in a sample obtained from the patient the expression level of NKp46 ii) comparing the expression level determined at step i) with its predetermined reference value... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

04/06/17 / #20170096710

Methods for predicting response to hdaci/dnmti combination in multiple myeloma

)... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

03/23/17 / #20170079970

Tetrahydroquinoline derivatives and their use as epac1 inhibitors for the treatment of myocardial infarction injury

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a method for providing cardioprotection in a subject who experienced a myocardial infarction comprising administering the subject with a therapeutically effective amount of at least... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

03/23/17 / #20170079958

Mif inhibitors for the acute or chronic treatment of pulmonary hypertension

The present invention relates to the use of compounds of general Formula I and pharmaceutically acceptable enantiomers, salts or solvates thereof, for treating pulmonary hypertension in a subject.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

03/16/17 / #20170073733

Carbapenemase and antibacterial treatment

The present invention relates to a carbapenemase and methods using said carbapenemase such as detection methods, screening methods, predictive methods and therapeutic uses.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

03/02/17 / #20170058010

Methods and pharmaceutical compositions for the treatment of cancer

The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. In particular, the present invention relates to a polypeptide comprising or consisting of i) an amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

02/23/17 / #20170049862

Methods and pharmaceutical compositions for treating vaso-occlusive crisis

The present invention relates to methods and pharmaceutical compositions for treating vaso-occlusive crises. In particular, the present invention relates to a method of treating a vaso-occlusive crisis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of agent capable of degrading, destabilizing or depleting... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

02/16/17 / #20170044623

New biomarker for aml

The present invention relates to an in vitro method for predicting the survival time of a subject suffering from acute myeloid leukemia (AML) comprising determining, in a biological sample from the subject, the epigenetic profile of the H3K27.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

02/16/17 / #20170044234

Polypeptides and uses thereof for reducing cd95-mediated cell motility

The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

02/16/17 / #20170045512

Methods for the diagnostic of an autoimmune disease

An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

02/09/17 / #20170035842

Apoo for use in a treating cancer and various pathophysiological situations

The invention relates to a compound for use for inducing apoptosis in a cancerous cell, wherein said compound is selected from the group consisting of ApoO, a variant or a fragment thereof, their mixtures, and a vector encoding for said ApoO, variant or fragment thereof. The invention further relates to... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

02/02/17 / #20170029487

Selective inhibitors of c-fos and their antiproliferative properties

Selective inhibitor of c-Fos and their antiproliferative properties The invention relates to selective inhibitor of c-Fos for use in the prevention and/or treatment of cancers and restenosis.... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale

01/26/17 / #20170021001

An isolated donor mhc-derived peptide and uses thereof

The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to an isolated peptide of 15 or 16 amino acids long that comprises or consists of... Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###